UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 2, 2011
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
|
DELAWARE
|
000-51436
|
20-2903526
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
248 Route 25A, No. 2
East Setauket, New York 11733
(Address of principal executive offices)
(631) 942 7959
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Effective May 2, 2011, Robert Royds was elected to the Company’s Board of Directors to fill a vacancy on the Board. Dr. Royds is to receive five-year options to purchase an aggregate of 200,000 shares of the Company’s Common Stock, vesting 25,000 quarterly commencing May 1, 2011, at an exercise price of $0.98 per share.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: May 2, 2011
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
|
||
|
By:
|
/s/ John S. Kovach
|
||
|
John S. Kovach, Chief Executive Officer
|
|||